Epigenetic control of skeletal development by the histone methyltransferase Ezh2

Amel Dudakovic, Emily T. Camilleri, Fuhua Xu, Scott M. Riester, Meghan E. McGee-Lawrence, Elizabeth W. Bradley, Christopher R. Paradise, Eric A. Lewallen, Roman Thaler, David R. Deyle, A. Noelle Larson, David G. Lewallen, Allan B. Dietz, Gary S. Stein, Martin A. Montecino, Jennifer J. Westendorf, Andre J. Van Wijnen

Resultado de la investigación: Article

56 Citas (Scopus)

Resumen

Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

Idioma originalEnglish
Páginas (desde-hasta)27604-27617
Número de páginas14
PublicaciónJournal of Biological Chemistry
Volumen290
N.º46
DOI
EstadoPublished - 13 nov 2015

Huella dactilar

Osteoblasts
Epigenomics
Bone
Polycomb-Group Proteins
Extracellular Matrix Proteins
Osteogenesis
Gene expression
Histones
Small Interfering RNA
Lysine
Chromatin
Cranial Sutures
Cells
Throughput
RNA
Tissue
RNA Sequence Analysis
Craniosynostoses
Cell Cycle Proteins
Growth Plate

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Citar esto

Dudakovic, A., Camilleri, E. T., Xu, F., Riester, S. M., McGee-Lawrence, M. E., Bradley, E. W., ... Van Wijnen, A. J. (2015). Epigenetic control of skeletal development by the histone methyltransferase Ezh2. Journal of Biological Chemistry, 290(46), 27604-27617. https://doi.org/10.1074/jbc.M115.672345
Dudakovic, Amel ; Camilleri, Emily T. ; Xu, Fuhua ; Riester, Scott M. ; McGee-Lawrence, Meghan E. ; Bradley, Elizabeth W. ; Paradise, Christopher R. ; Lewallen, Eric A. ; Thaler, Roman ; Deyle, David R. ; Larson, A. Noelle ; Lewallen, David G. ; Dietz, Allan B. ; Stein, Gary S. ; Montecino, Martin A. ; Westendorf, Jennifer J. ; Van Wijnen, Andre J. / Epigenetic control of skeletal development by the histone methyltransferase Ezh2. En: Journal of Biological Chemistry. 2015 ; Vol. 290, N.º 46. pp. 27604-27617.
@article{0b8bf446d968488caef5b25a3ae0732b,
title = "Epigenetic control of skeletal development by the histone methyltransferase Ezh2",
abstract = "Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.",
author = "Amel Dudakovic and Camilleri, {Emily T.} and Fuhua Xu and Riester, {Scott M.} and McGee-Lawrence, {Meghan E.} and Bradley, {Elizabeth W.} and Paradise, {Christopher R.} and Lewallen, {Eric A.} and Roman Thaler and Deyle, {David R.} and Larson, {A. Noelle} and Lewallen, {David G.} and Dietz, {Allan B.} and Stein, {Gary S.} and Montecino, {Martin A.} and Westendorf, {Jennifer J.} and {Van Wijnen}, {Andre J.}",
year = "2015",
month = "11",
day = "13",
doi = "10.1074/jbc.M115.672345",
language = "English",
volume = "290",
pages = "27604--27617",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "46",

}

Dudakovic, A, Camilleri, ET, Xu, F, Riester, SM, McGee-Lawrence, ME, Bradley, EW, Paradise, CR, Lewallen, EA, Thaler, R, Deyle, DR, Larson, AN, Lewallen, DG, Dietz, AB, Stein, GS, Montecino, MA, Westendorf, JJ & Van Wijnen, AJ 2015, 'Epigenetic control of skeletal development by the histone methyltransferase Ezh2', Journal of Biological Chemistry, vol. 290, n.º 46, pp. 27604-27617. https://doi.org/10.1074/jbc.M115.672345

Epigenetic control of skeletal development by the histone methyltransferase Ezh2. / Dudakovic, Amel; Camilleri, Emily T.; Xu, Fuhua; Riester, Scott M.; McGee-Lawrence, Meghan E.; Bradley, Elizabeth W.; Paradise, Christopher R.; Lewallen, Eric A.; Thaler, Roman; Deyle, David R.; Larson, A. Noelle; Lewallen, David G.; Dietz, Allan B.; Stein, Gary S.; Montecino, Martin A.; Westendorf, Jennifer J.; Van Wijnen, Andre J.

En: Journal of Biological Chemistry, Vol. 290, N.º 46, 13.11.2015, p. 27604-27617.

Resultado de la investigación: Article

TY - JOUR

T1 - Epigenetic control of skeletal development by the histone methyltransferase Ezh2

AU - Dudakovic, Amel

AU - Camilleri, Emily T.

AU - Xu, Fuhua

AU - Riester, Scott M.

AU - McGee-Lawrence, Meghan E.

AU - Bradley, Elizabeth W.

AU - Paradise, Christopher R.

AU - Lewallen, Eric A.

AU - Thaler, Roman

AU - Deyle, David R.

AU - Larson, A. Noelle

AU - Lewallen, David G.

AU - Dietz, Allan B.

AU - Stein, Gary S.

AU - Montecino, Martin A.

AU - Westendorf, Jennifer J.

AU - Van Wijnen, Andre J.

PY - 2015/11/13

Y1 - 2015/11/13

N2 - Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

AB - Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

UR - http://www.scopus.com/inward/record.url?scp=84946925427&partnerID=8YFLogxK

U2 - 10.1074/jbc.M115.672345

DO - 10.1074/jbc.M115.672345

M3 - Article

C2 - 26424790

AN - SCOPUS:84946925427

VL - 290

SP - 27604

EP - 27617

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 46

ER -

Dudakovic A, Camilleri ET, Xu F, Riester SM, McGee-Lawrence ME, Bradley EW y otros. Epigenetic control of skeletal development by the histone methyltransferase Ezh2. Journal of Biological Chemistry. 2015 nov 13;290(46):27604-27617. https://doi.org/10.1074/jbc.M115.672345